

January 9, 2026

The Manager- Listing
BSE Limited
Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort
Mumbai – 400 001

The Manager- Listing
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1, G - Block
Bandra -Kurla Complex, Bandra (E)
Mumbai – 400 051

Dear Sir(s),

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Appointment of Senior Management Personnel

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointments of Ms. Aditi Dayarus Mehta as Director – Oncology Business Unit and Mr. Nitin Bindal as Director - Institutional Business & Public Channels with effect from January 12, 2026.

In this regard, please find the details as required under the SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, attached herewith as **Annexure – A**.

Kindly take the above information on record.

Thanking you

For AstraZeneca Pharma India Limited

Praveen Rao Akkinepally
Managing Director

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

Annexure - A

Sl. No.	Particulars	Ms. Aditi Dayarus Mehta	Mr. Nitin Bindal
1	Reason for change viz. appointment, resignation, removal, death or otherwise;	Ms. Aditi Dayarus Mehta as Director – Oncology Business Unit	Mr. Nitin Bindal as Director - Institutional Business & Public Channels
2	Date of appointment/ cessation (as applicable) and term of appointment	Effective January 12, 2026 Term of appointment – Full – time employment	Effective January 12, 2026 Term of appointment – Full – time employment
3	Brief Profile	<p>Ms. Aditi Dayarus Mehta is a seasoned pharmaceutical professional with over 15 years of experience in Commercial Leadership, Strategy, and Change Management. She joins us from Pfizer India where she spent over a decade across numerous roles: Oncology, Access, Commercial Excellence and most recently was the Business Unit Director leading Pfizer's Innovative Vaccine portfolio. Prior to Pfizer India, Aditi was a Business Analyst at Bristol Myers Squibb.</p> <p>Known to be a passionate enterprise leader, Aditi has led transformative commercial growth, rooted deeply in the values of equity & excellence. Her diverse expertise lends strategic orientation to effectively lead collaborative teams.</p> <p>A Pharmacy Gold Medallist, she holds a degree in Bachelor of Pharmacy from K.M. Kundnani College of Pharmacy, Mumbai.</p>	<p>Nitin has over 17 years of diverse experience in the pharmaceutical industry across multiple therapeutic areas and functions.</p> <p>In a distinguished career at Bristol Myers Squibb (BMS), Nitin served as Business Unit Director – Oncology & Haematology, where he led access and market penetration for immunotherapies across 20 indications.</p> <p>Prior to BMS, Nitin spent over eight years at Johnson & Johnson (J&J), where he held key roles including National Sales Head and Senior Marketing Manager in Oncology, and led the Neuroscience Business Unit. Before J&J he has significantly contributed to strategy and commercial roles at organisations such as Novartis, Wockhardt, and Smart Analyst.</p> <p>He holds a degree in Chemical Engineering from IIT Bombay and a Post Graduate Program in Management for Executives from UCLA Anderson School of Management (Los Angeles, CA, USA).</p>
4	Disclosure of relationships between directors	Not Applicable	Not Applicable